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Abstract
Purpose:  To  evaluate  the  possible  use  of  soft  contact  lenses  (CL)  to  improve  the  secretagogue
role of  diadenosine  tetraphosphate  (Ap4A)  promoting  tear  secretion.
Methods:  Two  conventional  hydrogel  CL  (Omaﬁlcon  A  and  Ocuﬁlcon  D)  and  two  silicone  hydrogel
(SiH) CL  (Comﬁlcon  A  and  Balaﬁlcon  A)  were  used.  Ap4A  was  loaded  into  the  lenses  by  soaking
in a  1  mM  Ap4A  solution  during  12  h.  In  vitro  experiments  were  performed  by  placing  the  lenses
in multi-wells  during  2  h  containing  1  ml  of  ultrapure  water.  100  l  aliquots  were  taken  at  time
zero and  every  minute  for  the  ﬁrst  10  min,  and  then  every  15  min.  In  vivo  experiments  were
performed in  New  Zealand  rabbits  and  both  the  dinucleotide  release  from  SiH  and  tear  secretion
were measured  by  means  of  Schirmer  strips  and  high-pressure  liquid  chromatography  (HPLC)
analysis.
Results: Ap4A  in  vitro  release  experiments  in  hydrogel  CL  presented  a  release  time  50  (RT50)  of
3.9 ±  0.2  min  and  3.1  ±  0.1  min  for  the  non-ionic  and  the  ionic  CL,  respectively.  SiH  CL  released
also Ap4A  with  RT50 values  of  5.1  ±  0.1  min  for  the  non-ionic  and  2.7  ±  0.1  min  for  the  ionic  CL.
In vivo  experiments  with  SiH  CL  showed  RT50 values  of  9.3  ±  0.2  min  and  8.5  ±  0.2  min  for  the
non-ionic  and  the  ionic  respectively.  The  non-ionic  lens  Ap4A  release  was  able  to  induce  tear
secretion above  baseline  tear  levels  for  almost  360  min.
Conclusion:  The  delivery  of  Ap4A  is  slower  and  the  effect  lasts  longer  with  non-ionic  lenses  than
ionic lenses.
©  2013  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Administración  in  vitro  e  in  vivo  del  secretagogo  diadenosín  tetrafosfato  utilizando
lentes  de  contacto  blandas  convencionales  y  de  hidrogel  de  silicona
Resumen
Objetivo:  Evaluar  el  posible  uso  de  las  lentes  de  contacto  blandas  (LC)  para  mejorar  la  función
secretagoga  del  diadenosín  tetrafosfato  (Ap4A),  de  cara  a  promover  la  secreción  lagrimal.
Métodos:  Se  utilizaron  dos  lentes  de  contacto  convencionales  de  hidrogel  (Omaﬁlcon  A  y  Ocu-
ﬁlcon D)  y  dos  lentes  de  contacto  de  hidrogel  de  silicona  (SiH)  (Comﬁlcon  A  y  Balaﬁlcon  A).  Se
cargó Ap4A  en  las  lentes,  mediante  inmersión  en  una  solución  de  1  mM  de  Ap4A  durante  12  h.  Se
realizaron experimentos  in  vitro,  colocando  las  lentes  durante  2  h  en  pocillos  con  1  ml  de  agua
ultra pura.  Se  tomaron  100  l  de  muestra  en  el  momento  inicial,  y  a  cada  minuto  durante  los
primeros diez  minutos,  y  posteriormente  cada  15  minutos.  Se  realizaron  experimentos  in  vivo
con conejos  de  Nueva  Zelanda,  midiéndose  tanto  la  liberación  de  nucleótido  a  partir  de  las
lentes SiH  como  la  secreción  de  lágrimas,  mediante  tiras  de  Schirmer  y  análisis  cromatografía
líquida de  alta  presión  (HPLC).
Resultados:  Los  experimentos  de  liberación  in  vitro  de  Ap4A  en  las  lentes  de  contacto  de  hidro-
gel presentaron  un  tiempo  de  liberación  50  (RT50),  de  3,9  ±  0,2  min  y  3,1  ±  0,1  min  para  las
lentes no  iónicas  e  iónicas,  respectivamente.  Las  lentes  de  contacto  de  SiH  liberaron  tam-
bién Ap4A  con  valores  RT50 de  5,1  ±  0,1  min  para  las  lentes  no  iónicas,  y  de  2,7  ±  0,1  min  para
las lentes  iónicas.  Los  experimentos  in  vivo  con  las  lentes  de  SiH  mostraron  valores  RT50 de
9,3 ±  0,2  min  y  de  8,5  ±  0,2  min  para  las  lentes  no  iónicas  y  las  iónicas,  respectivamente.  La
liberación  de  Ap4A  de  las  lentes  no  iónicas  fue  capaz  de  inducir  la  secreción  de  lágrimas  por
encima de  los  niveles  basales,  durante  casi  360  min.
Conclusión:  La  liberación  de  Ap4A  es  más  lenta,  y  el  efecto  es  más  duradero  con  lentes  no
iónicas que  con  lentes  iónicas.
© 2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
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ntroduction
he  eye  is  characterized  by  its  complex  structure  and  high
esistance  to  foreign  substances  including  drugs  that  makes
cular  drug  delivery  a  major  challenge.  Currently,  more
han  90%  of  ophthalmic  drugs  are  delivered  in  the  form  of
olutions  or  suspensions.1 These  conventional  ophthalmic
ormulations  generally  show  low  ocular  bioavailability  due
o  various  factors  such  as  reﬂex  tearing  and  blinking,  non-
roductive  absorption,  nasolacrimal  drainage,  metabolic
egradation,  and  the  relative  impermeability  of  the  corneal
pithelial  membrane.  As  a  consequence  of  these  physiolog-
cal  and  anatomical  constraints,  ophthalmic  drugs  have  a
hort  residence  time  of  less  than  5  min  and  only  1--5%  of
pplied  drug  is  effectively  absorbed.2 The  drug  loss  to  the
ystemic  circulation  leads  to  drug  wastage  and  it  could  cause
ndesirable  side  effects.
To  overcome  the  low  ocular  bioavailability  associated
ith  topical  ocular  administration  of  drugs  by  eye  drops,
lternative  drug  delivery  systems  have  been  proposed.3,4 In
his  context,  soft  contact  lenses  (CL)  are  emerging  as  new
ehicle  for  ophthalmic  drug  delivery.  In  the  eye,  CL  are  sepa-
ated  off  the  cornea  by  a  thin  ﬂuid  layer  called  post-lens  tear
lm.  The  ﬂuid  in  the  post-lens  tear  ﬁlm  is  not  well-mixed
ith  the  remaining  tear  ﬂuid.  The  mixing  time  of  the  ﬂuid
n  the  post  lens  tear  ﬁlm  with  the  outer  tear  ﬂuid  is  about
0  min.5 Thus,  ophthalmic  drugs  released  from  the  soft  CL
ould  have  a  residence  time  in  front  of  the  cornea  for  at
east  30  min  compared  to  less  than  5  min  for  eye  drops.6 The
nhanced  residence  time  leads  to  improved  drug  bioavail-
bility  that  would  reduce  the  amount  of  drug  that  enters  in
s
w
i
dhe  systemic  circulation,  thus  potentially  improving  thera-
eutic  efﬁcacy  and  preventing  side  effects.
The  potential  of  CL  loading  conventional  drugs  used  to
reat  anterior  eye  disorders  have  been  already  explored.7--10
ost  of  the  studies  performed  have  been  in  vitro  assays,
hereas  in  vivo  validation  of  therapeutic  contact  lenses  has
ot  been  so  widely  examined.
Commercially  available  CL  are  manufactured  using  dif-
erent  materials  presenting  signiﬁcant  changes  in  their
ater  content  and  electrostatic  charge  among  other  char-
cteristic  properties.11 These  material  variations  can  have  a
elevant  effect  on  the  CL--drug  interaction,  and  thus  affect
ates  of  drug  uptake  and  release.
Initial  studies  were  developed  soaking  hydrophilic  con-
entional  soft  contact  lens  based  on  poly  (2-hydroxyethyl
ethacrylate)  (pHEMA)  hydrogels.11--15 However,  in  the  last
ears,  highly  oxygen-permeable  soft  CL  based  on  siloxane
ontaining  hydrogels,  have  also  been  tested.16--20 As  silicone-
ydrogel  (SiH)  contact  lenses  transmit  more  oxygen  than
onventional  materials,  thus,  diminishing  in  most  of  the
ases  the  clinical  hypoxic  signs  associated  with  extended
ear  of  hydrophilic  contact  lenses,  they  may  represent  a
etter  option  to  develop  extended  drug  delivery  vehicles
or  therapeutic  applications.
New  substances  are  emerging  as  potential  agents  for  the
reatment  of  dry  eye.  Among  these,  dinucleotides  are  inter-
sting  candidates  as  their  topical  application  induces  tear
ecretion  stimulating  the  secretion  of  tear  ﬂuid  (water)  as
ell  as  the  secretion  of  mucins  (key  proteins  contribut-
ng  to  maintenance  and  lubrication  of  the  tear  ﬁlm).  The
inucleotide  diadenosine  tetraphosphate  (Ap4A)  markedly
Contact  lens  delivery  of  Ap4A  207
Table  1  Characteristics  of  the  contact  lenses  used  along  this  study.
Lenses  Hydrogel  conventional
non-ionic
Hydrogel
conventional  ionic
Silicone  hydrogel
non-ionic
Silicone
hydrogel  ionic
Commercial  name  (supplier)  Proclear
(CooperVision)
Biolens  55  (Tiedra)  Bioﬁnity
(CooperVision)
Pure  Vision  II
(Bausch  &
Lomb)
Material name  (USAN)  Omaﬁlcon  A  Ocuﬁlcon  D  Comﬁlcon  A  Balaﬁlcon  A
Water content  (%)  62  55  48  36
Center thickness  in  mm  (at  −3.00  D)  0.065  0.070  0.080  0.070
Oxygen permeability  (×10−11)  Dk  27  --  128  91
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increased  tear  production  to  around  a  60%  above  normal
tear  values  in  New  Zealand  White  rabbits.21 Likewise,  the
application  of  other  dinucleotide,  diuridine  tetraphosphate
(Up4U,  INS365,  diquafosol),  induced  a  1.5-fold  transient
increase  in  tear  ﬂuid  secretion  in  a  rat  dry  eye  model.22
Interestingly,  this  dinucleotide  has  been  under  development
as  a  new  treatment  for  dry  eye23 and,  after  completion  of
clinical  trials,  it  has  been  recently  launched  in  Japan  by
Santen  Pharmaceutical.
The  purpose  of  this  study  was  to  investigate  the  delivery
of  the  dinucleotide  Ap4A  from  commercial  soft  CL  perform-
ing  in  vitro  and  in  vivo  assays.  Furthermore,  to  obtain  an
indication  of  the  clinical  feasibility  of  this  drug  delivery  sys-
tem  to  treat  dry  eye  pathology,  we  measured  tear  secretion
induced  by  Ap4A  soaked-soft  contact  lenses.
Methods
Materials
Four  commercially  available  CL,  including  two  conventional
hydrogel  lenses  (Omaﬁlcon  A  and  Ocuﬁlcon  D)  and  two  SiH  CL
(Comﬁlcon  A  and  Balaﬁlcon  A),  which  properties  are  outlined
in  Table  1,  were  evaluated  in  this  study.  All  lenses  had  a
power  of  −3.00  D  and  base  curve  of  8.60  mm.  Diadenosine
tetraphosphate  (Ap4A)  was  purchased  from  Sigma--Aldrich
Chemicals  (St.  Louis,  USA).  The  Schirmer  strips  (Tear  Flo  test
strips,  HUB  Pharmaceuticals  Rancho  Cucamonga,  USA)  were
provided  by  Laboratorios  Lenticon  SA  (Spain).  All  chemicals
were  of  reagent  grade  purchased  from  Merck  (Germany).
Animals
Four  male  New  Zealand  white  rabbits  (2.5  ±  0.5  kg)  were
used  in  the  in  vivo  experimentation.  The  animals  were  kept
in  individual  cages  with  free  access  to  food  and  water.
Rabbits  were  submitted  to  12  h/12  h  light/dark  cycles.  All
the  protocols  here  described  were  approved  by  the  Comité
de  Experimentación  Animal  of  Complutense  University  which
follows  the  tenets  of  the  European  Communities  Council
Directive  (86/609/EEC).Ap4A  loading  into  contact  lenses
Commercial  CL  were  removed  from  their  original  blister
packs  and  were  transferred  to  24-well  plate.  Ap4A  was
c
t
t
l19.2  160  130
oaded  into  the  lenses  by  soaking  in  a  1  mM  Ap4A  solution
diluted  in  saline  solution  sterile  at  0.9%  whose  properties
ere  the  same  than  CL’  packaging  solutions).  The  lenses
ere  soaked  overnight  for  12  h  simulating  a normal  cleaning
egime  performed  by  wearers  of  contact  lenses.  The  con-
rol  CL  was  soaked  in  saline  solution  at  0.9%.  At  the  end
f  Ap4A  loading,  the  lenses  were  taken  out  and  the  excess
p4A  from  the  surface  was  removed  before  to  beginning  the
p4A  release  experiments.  The  procedure  was  the  same  for
‘in  vivo’’ and  ‘‘in  vitro’’ studies.
p4A  release  ‘‘in  vitro’’  assays
or  each  release  experiment,  three  CL  of  each  lens  type
ere  studied.  After  Ap4A  loading,  the  lenses  were  placed  in
ew  well  containing  1  ml  ultrapure  water.  Samples  (aliquots
f  100  l)  were  removed  from  the  well  at  time  zero  and
very  minute  for  the  ﬁrst  10  min,  and  then  at  t  =  15,  20,
0,  60,  90  and  120  min,  to  assess  the  quantity  of  Ap4A
eleased  into  the  solution.  The  same  volume,  which  was
emoved  in  each  sample,  was  replaced  with  ultrapure  water.
he  Ap4A  release  dynamics  was  determined  by  measuring
he  quantity  of  Ap4A  in  each  sample,  which  was  mea-
ured  by  means  of  high-pressure  liquid  chromatography
HPLC).
p4A  release  ‘‘in  vivo’’  assays
he  in  vivo  experiments  were  done  with  SiH  contact  lenses,
hich  were  loaded  with  Ap4A  as  described  above.  In  vivo
ssays  study  two  topics,  the  dynamic  of  Ap4A  release
‘in  vivo’’ via  CL  and  its  effect  on  tear  secretion.  Both
ere  measured  by  means  of  Schirmer  strips.  Firstly,  base-
ine  values  were  measured.  Then,  each  animal  received  to
ight  eye  one  drop  of  10  l of  Ap4A  at  1  mM,  a  Comﬁlcon
 (non-ionic)  contact  lens  loaded  with  Ap4A  or  a  Balaﬁl-
on  A  (ionic)  contact  lens  loaded  with  Ap4A.  In  each  case,
he  contralateral  eye  receives  the  same  lens  but  without
p4A.  After  that,  tear  secretion  was  measured  using  the
chirmer  test  without  anesthesia  at  t =  0,  5,  10,  15,  30,  45,
0,  90,  120  and  then  every  hour  during  6  h.  Tear  collection
as  always  performed  following  a  van  Bijsterveld  modiﬁed
riterion.24 Brieﬂy,  the  Schirmer  strip  was  placed  on  the
emporal  tarsal  conjunctiva  of  the  lower  lid  for  2  min25 with
he  eyes  closed.  The  volume  of  tears  was  recorded  as  mil-
imeters  of  moistened  strip,  and  the  wetted  ends  of  the
2 C.O.  Dominguez-Godinez  et  al.
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Figure  1  In  vitro  release  of  diadenosine  tetraphosphate  from
soft contact  lenses.  (A)  Representative  chromatographic  pro-
ﬁle showing  the  release  of  Ap4A  from  a  non-ionic  hydrogel
contact  lens.  (B)  Comparative  in  vitro  release  of  Ap4A  from  non-
ionic and  ionic  hydrogel  lenses  following  the  protocol  described
in methods  (n  =  3).  (C)  Comparative  in  vitro  release  of  Ap4A
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chirmer  strip  were  placed  in  Eppendorf  tubes  containing
00  l  of  ultrapure  water,  until  the  HPLC  analysis  was  per-
ormed.
The  reason  for  not  using  conventional  hydrogel  lenses
as  the  problems  we  observed  when  these  lenses  were  ﬁt-
ed  to  rabbit  eyes.  Due  to  the  low  frequency  of  blinking,
he  rate  of  dryness  did  not  permit  us  to  perform  accurate
easurements  and  therefore  we  decided  to  focus  on  SiH
enses.
ample  preparation  for  analysis
ample  from  ‘‘in  vivo’’ and  ‘‘in  vitro’’ assays  were  col-
ected  after  the  corresponding  procedure  (see  above).
amples  were  stored  in  Eppendorf  tubes  at  −20 ◦C  before
rocessing.  The  treatment  was  based  on  the  protocol
escribed  by  Lazarowski  and  co-workers.26 Brieﬂy,  samples
ere  heated  at  98 ◦C  bath  for  2  min.  Then,  the  samples
ere  incubated  in  ice  for  10  min  and  ﬁnally  the  residues
ere  removed  by  centrifugation  at  13,000  rpm  for  10  min.
inally,  the  supernatants  were  collected  for  HPLC  analy-
is.
PLC  procedures
he  chromatographic  system  consisted  of  a  Waters  1515  Iso-
ratic  HPLC  pump,  a  2487  dual  absorbance  detector,  and  a
eodyne  injector,  all  managed  by  the  software  Breeze  from
aters  (Milford,  MA).  The  column  was  a  KromaPhase  100
18  (250  mm  in  length,  4.6  mm  in  diameter)  from  Scharlab.
he  system  was  equilibrated  overnight  with  10  mM  KH2PO4,
 mM  tetrabutylammonium  (TBA),  21%  acetonitrile,  pH  7.5,
nd  detection  of  nucleotides  was  performed  under  isocratic
onditions  with  the  mobile  phase  described  above  at  a  ﬂow
ate  of  2  ml/min.
After  injection  of  100  l of  sample,  detection  was  mon-
tored  at  254  nm.  Ap4A  peak  was  identiﬁed  comparing  their
etention  time  with  the  one  of  a  commercial  standard.  The
uantiﬁcation  was  performed  by  comparing  the  areas  under
he  curves  with  those  of  known  amounts  of  commercial
tandard  Ap4A.
tatistical  analysis
ll  data  are  presented  as  the  mean  ±  SD.  Due  to  the
imited  sample  size,  comparisons  between  lenses  were
one  using  non-parametric  statistical  analysis.  Differences
etween  time  points  were  determined  by  Kruskal--Wallis
est.  Repeated  measures  analysis  was  conducted  using
ilcoxon  signed  ranks  test.  All  graphics  were  carried  out
y  GraphPad  Prism  5  software  (GraphPad,  La  Jolla,  CA).
p4A  release  (decay  constant)  was  calculated  by  ﬁtting
he  corresponding  curves  to  one  phase  exponential  decay
urve.  From  this  analysis  it  was  possible  to  calculate  the
elease  Time  50  (RT50),  which  corresponds  to  the  time
n  which  the  lens  has  released  50%  of  the  maximum
p4A  measured.  With  this  analysis  it  has  been  also  pos-
ible  to  obtain  the  rate  of  release  for  each  lens.  A  p
alue  lower  than  0.05  was  considered  statistically  signiﬁ-
ant.
t
a
lrom  non-ionic  and  ionic  silicon  lenses  following  the  protocol
escribed  in  methods  (n  =  3).
esults
p4A  release  ‘‘in  vitro’’
he  release  of  the  dinucleotide  Ap4A  was  followed  by  HPLC
y  measuring  its  absorbance  at  254  nm  wavelength.  As  pre-
ented  in  Fig.  1A  for  a  non-ionic  hydrogel  lens,  where  a  series
f  HPLC  injections  are  plotted,  the  release  of  the  loaded
inucleotide  presented  a  maximal  release  at  2  min  after  the
n  vitro  experiment  started.  After  this  maximal  peak,  the
mount  of  released  Ap4A  was  gradually  diminishing  until  the
nd  of  the  experiments  (360  min).
Four  types  of  lenses  were  used  in  this  study,  two  conven-
ional  hydrogel  lenses,  Omaﬁlcon  A  (ionic;  55%  hydration)
nd  Balaﬁlcon  A  (non-ionic;  62%  hydration)  and  two  SiH
enses,  Conﬁlcon  A  (ionic;  36%  hydration)  and  Balaﬁlcon  A
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Figure  2  In  vivo  release  of  diadenosine  tetraphosphate  from
silicon  contact  lenses  and  effect  on  tear  secretion.  (A)  In  vivo
release  of  Ap4A  from  non-ionic  and  ionic  silicon  contact  lenses
together  with  a  topical  application  of  1  mM  Ap4A  (10  l)  (n  =  3).
(B) Variation  of  tear  secretion,  induced  by  Ap4A  released  from
non-ionic  and  ionic  silicon  contact  lenses  together  with  a  topi-
cal application  of  1  mM  Ap4A  (10  l)  (n  =  3).  Zero  represents  the
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(non-ionic;  48%  hydration).  For  a  better  understanding,  the
study  of  how  Ap4A  was  released  in  vitro  from  the  lenses
was  grouped  by  lens  materials.  As  it  can  be  seen  in  Fig.  1B,
hydrogel  lenses  presented  a  peak  of  1747  ±  175  pmol  and
1227  ±  120  pmol,  2  min  after  the  experiment  started,  for
the  Omaﬁlcon  A  (non-ionic)  and  the  Oculﬁlcon  A  (ionic)
lens  respectively  (p  =  0.017;  Wilcoxon  test).  Both  contact
lenses  presented  release  time  50  (RT50)  of  3.9  ±  0.2  min
and  3.1  ±  0.1  min  for  the  Omaﬁlcon  A  and  Oculﬁlcon  A
lens  respectively.  The  rate  of  the  released  of  Ap4A  per-
mitted  us  to  obtain  decay  constant  (decay  rate)  values  of
0.17  ±  0.02  min−1 for  the  Omaﬁlcon  A  lens  and  a  value  of
0.22  ±  0.02  min−1 for  Ocuﬁlcon  A  lens  (all  the  experiments
n  =  3).
When  the  same  protocol  was  performed  with  the  SiH
lenses,  the  Comﬁlcon  A  (non-ionic)  lens  presented  a  peak  of
982  ±  130  pmol  of  Ap4A,  and  the  Balaﬁlcon  A  (ionic)  provided
a  maximal  release  of  550  ±  78  pmol  of  Ap4A,  both  peaks
2  min  after  the  experiment  started.  (p  =  0.011;  Wilcoxon
test).  The  RT50 for  both  lenses  were  5.1  ±  0.1  min  for  the
Comﬁlcon  A  and  2.7  ±  0.1  min  for  the  Balaﬁcon  A  contact
lens.  The  Ap4A  decay  constant  values  for  these  lenses  were
0.13  ±  0.01  min−1 for  the  Comﬁlcon  A  and  0.25  ±  0.04  min−1
for  the  Balaﬁlcon  A  lens  (n  =  3  in  all  experiments).
Ap4A  release  ‘‘in  vivo’’
Since  the  lens  that  provided  the  longest  RT50 value  was  the
Comﬁlcon  A  (non-ionic)  lens,  we  took  this  material  for  our
‘‘in  vivo’’ studies  in  New  Zealand  rabbits.  In  this  sense,  we
compared  whether  or  not  the  ionic  nature  of  the  contact  lens
could  be  a  relevant  aspect  considering  the  chemical  charac-
teristics  of  the  dinucleotide  Ap4A.  In  Fig.  2A  is  presented  a
comparison  between  the  Comﬁlcon  A  (non-ionic)  lens  with
the  Balaﬁlcon  A  (ionic),  both  loaded  with  Ap4A,  and  also
the  topical  application  of  the  dinucleotide,  in  New  Zealand
rabbits.  The  maximal  Ap4A  concentration  released  was  pro-
vided  by  the  Balaﬁlcon  A  lens,  with  a  peak  of  34.9  ±  7.0  M,
while  the  Comﬁlcon  A  peak  was  14.2  ±  6.0  M  (p  =  0.034;
Wilcoxon  test).  The  topical  application  of  Ap4A  presented
a  peak  of  90.5  ±  9.0  M.
Interestingly,  the  way  the  two  lenses  and  the  topical
application  of  Ap4A  was  released  ‘‘in  vivo’’, demon-
strated  that  the  lens  that  delivered  Ap4A  more  slowly
was  the  Comﬁlcon  A  (non-ionic)  lens.  The  RT50 for  the
Comﬁlcon  A,  Balaﬁlcon  A  and  topical  application  of  Ap4A
were,  9.3  ±  0.2  min,  8.5  ±  0.2  min  and  4.9  ±  0.1  min  respec-
tively  (n  =  3).  Concerning  the  decay  constant,  the  values
obtained  were  0.07  ±  0.05  min−1 for  the  Comﬁlcon  A  (non-
ionic)  lens  and  0.08  ±  0.06  min−1 for  Balaﬁlcon  A  lens
(n  =  3).
When  the  ability  of  the  lens-released  Ap4A  to  mod-
ify  tear  secretion  was  tested  in  New  Zealand  rabbits,  it
was  possible  to  see  that  the  longest  effect  on  tear  secre-
tion  was  obtained  by  the  Ap4A  that  was  released  from  the
Comﬁlcon  A  (non-ionic)  lens,  as  presented  in  Fig.  2B.  The
effect  was  measurable  up  to  360  min,  compared  to  the
Balaﬁlcon  A  (ionic)  which  lasted  less  than  1  h.  Interest-
ingly,  the  topically  applied  Ap4A  although  producing  a  strong
effect,  12  mm  in  Schirmer  test,  its  effect  only  lasted  90  min
(n  =  3).
c
c
F
taseline  tear  secretion  which  corresponded  to  a  Schirmer  score
f 12  ±  1  mm.
iscussion
o  date,  there  are  no  published  data  regarding  the  deliv-
ry  of  dinucleotides  from  CL  for  dry  eye  treatment  or  in
nother  condition.  The  present  work  reports  the  ﬁrst  study
hat  has  assessed  the  in  vitro  and  in  vivo  release  of  Ap4A
rom  conventional  soft  CL.
We  have  chosen  two  conventional  hydrogel  lenses
Omaﬁlcon  A  which  is  non-ionic  and  Ocuﬁlcon  D  which  is
onic)  and  two  silicone-hydrogel  contact  lenses  (Comﬁlcon
 which  is  non-ionic  and  Balaﬁlcon  A  which  is  ionic)  with
imilar  parameters  (diameter,  base  curve  and  center  thick-
ess),  because  the  aim  of  the  assay  has  been  to  compare  the
ifferent  behavior  in  the  Ap4A  loading  and  release  accord-
ng  to  material  and  in  relation  to  surface  charge  properties
ionic  or  non-ionic).  Incorporation  of  a drug  into  the  lens
an  be  achieved  by  different  techniques  such  as  drug-loaded
olloidal  nanoparticles,  molecular  imprinting,  or  soaking.8
or  this  ﬁrst  stage,  we  have  chosen  soaking  the  lenses  in
he  dinucleotide  solution  because  is  the  simplest  way  to
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ncorporate  the  drug  into  conventional  soft  CL.  When  CL  are
oaked  in  a  solution  containing  the  drug,  the  compound  dif-
uses  into  the  gel-like  matrix  of  the  lens,  where  it  is  trapped
ong  enough  to  be  released  when  transferred  to  the  tear
lm.27
A  number  of  research  groups  working  on  the  devel-
pment  of  therapeutic  CL  have  focused  on  delivery  of
ry  eye  medications  from  the  lenses.  Various  molecules
cting  as  re-wetting  agents  such  as  hyaluronic  acid  or
ydroxypropyl  methylcellulose  have  been  included  in  soft
L  and  their  subsequent  release  has  been  analyzed.28--30
owever,  soaked  CL  with  hyaluronic  acid  solution  did  not
oad  sufﬁcient  amounts  of  hyaluronic  acid  and  release  was
omplete  in  less  than  1 h.29 Considering  the  inﬂammatory
tiology  of  the  disease,  delivery  of  the  anti-inﬂammatory
rug  cyclosporine  A  from  soaked  contact  lenses  has
lso  been  proposed  for  dry  eye  treatment,  maintaining
yclosporine  A  delivery  rates  within  the  therapeutic  win-
ow  for  14  days.19 Our  in  vitro  outcomes  show  that  Ap4A
as  released  at  least  2  h  with  all  soaked  contact  lenses,
eing  the  SiH  non-ionic  lens  with  more  slowdown  release
ate.
Chemical  properties  and  water  content  have  been  sug-
ested  as  important  contact  lens  properties  inﬂuencing  drug
elivery.11 Conventional  hydrogel  CL  are  made  in  polyHEMA
hich  are  hydrophilic,31 meanwhile  SiH  CL  have  various
iloxane-based  monomers  and  therefore  the  material  is  less
ydrophilic.16 It  is  not  clear  if  the  release  is  correlated  with
he  drug  hydrophilicity.11 In  our  study  it  would  be  expected
hat  Ap4A  has  a  better  interaction  with  conventional  hydro-
el  lenses  than  silicone-hydrogel  lenses,  because  of  its
ydrophilic  properties.  In  fact,  hydrophilic  contact  lenses
elease  more  dinucleotide  than  SiH  lenses  in  the  ﬁrst  min-
tes  (see  Fig.  1).
Regarding  water  content,  drug  release  is  higher  in  CL
ith  more  water  content.  Probably  this  is  due  to  water  sol-
ates  and  carries  the  Ap4A  through  the  CL  material.32 Ap4A
elivery  correlated  well  with  CL  water  content.  But  it  seems
hat  hydrophilicity  and  water  content  are  not  the  main  fac-
ors  inﬂuencing  the  dinucleotide  release.  The  ionic  charge
f  the  contact  lens  materials  could  be  the  major  factor  in
p4A  delivery.  In  this  sense,  it  is  important  to  note  that
p4A  is  a  dinucleotide  presenting  four  phosphates  that  in
eutral  pH  present  four  negative  charges.33 This  could  be
he  reason  why  those  lenses  with  ionic  charge,  which  is  also
egative,  may  repel  Ap4A.  This  may  produce  two  undesir-
ble  effects,  either  a  poor  load  of  the  dinucleotide  or/and
 fast  release  form  the  lens  due  to  the  repulsion  between
he  negative  charges  of  Ap4A  and  the  contact  lens  mate-
ial.  Moreover,  the  fact  of  ionic  contact  lenses  to  provide  a
lightly  longer  retention  of  the  dinucleotide,  strongly  sug-
ests  that  among  some  factors  to  be  studied,  charge  and
ater  content  of  the  lens  compete  for  both  the  loading  as
ell  dinucleotide  release.  This  point  deserves  more  atten-
ion  and  further  analysis.
Another  important  difference  between  both  SiH  lenses
s  the  presence  of  a  plasma  oxidation  surface  treatment  in
he  ionic  lens  Balaﬁlcon  A,  which  is  not  present  in  the  non-
onic  lens  Comﬁlcon  A.  Plasma  treatment  has  been  applied  to
he  ﬁrst  generation  of  SiH  CL  in  order  to  counterbalance  the
ydrophobic  nature  of  the  siloxane  moieties.  This  distinctive
haracteristic  could  also  play  a  role  in  the  kinetics  of  Ap4A
C
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ptake  and  release  that  need  to  be  further  investigated  in
uture  studies.
There  are  several  in  vitro  studies  about  drug  delivery
rom  CL  but  not  so  many  in  vivo  evaluating  the  in  vivo
elease  performance.  New  Zealand  white  rabbit  and  bea-
le  dog  are  the  most  commonly  used  models  in  drug
elivery  from  CL.18,34--36 Initially,  we  wanted  to  evaluate
ll  the  contact  lenses  studied  in  vitro  also  in  vivo, but
he  hydrogel  contact  lens  were  impossible  to  ﬁt  because
he  lenses  were  dried  in  the  ﬁrst  hour  of  wear  and  the
ictitating  membrane  expelled  the  lens  out  of  the  eye.
he  Comﬁlcon  A,  a  non-ionic  SiH,  maintained  the  Ap4A
oncentration  around  2  M  (value  established  as  a  concen-
ration  necessary  to  increase  tear  secretion21)  during  60  min
n  tear  ﬁlm,  compared  with  5  min  achieved  by  topical
dministration.  The  effect  of  Ap4A  delivered  from  Com-
lcon  A,  a  non-ionic  SiH,  on  the  tear  secretion  lasted
p  300  min,  5-fold  compared  with  Ap4A  presence  time  in
he  ocular  surface.  It  appears  that  P2Y2 receptors  present
n  the  main  lachrymal  and  accessory  glands37 are  stim-
lated  by  Ap4A  and  this  effect  remains  when  the  levels
f  the  dinucleotide  has  decreased  on  the  ocular  sur-
ace.
It is  known  the  involvement  of  Ap4A  in  the  ocular  surface
hysiopathology  stimulating  tear  secretion  or  improving  the
ate  of  corneal  wound  healing.  Therefore  the  dinucleotide
an  act  on  the  lachrymal  gland  to  induce  tear  secretion
nd  also  on  the  corneal  epithelium  accelerating  the  rate
f  migration  during  wound  healing.38,39 Both  roles  can  be
nhanced  when  Ap4A  is  delivered  from  CL.  In  particular,
nd  talking  about  tear  secretion,  the  dinucleotide  it  could
rovide  great  comfort  in  dry  eyes  and  it  could  be  partic-
larly  helpful  for  preventing  CL  induced  dry  eye  and/or
cular  injury.  Nevertheless,  it  is  necessary  to  be  careful
hen  extrapolating  these  in  vivo  results  obtained  in  ani-
al  models  to  humans  because  there  are  some  differences
etween  species  that  could  affect  the  dinucleotide  release.
he  most  important  difference  is  the  blinking  rate,  lower
n  rabbits,40 due  to  its  role  in  the  natural  release  of  Ap4A41
nd  also  its  relevance  in  the  CL  wear.  In  this  sense,  it  would
e  expected  better  results  with  humans,  since  they  blink
ore  often  permitting  higher  tonic  levels  of  Ap4A  due  to
link  shear  stress.41 Future  studies  should  be  conducted
n  order  to  evaluate  the  release  rate  with  different  din-
cleotides  concentrations.  Also,  it  could  be  interesting  to
est  its  potential  delivery  slowdown  with  others  drug-loaded
echniques.
In summary,  we  have  demonstrated  that  it  is  possible
o  use  commercially  available  CL  as  delivery  systems  for
 molecule  that  induces  tear  secretion.  Our  experiments
emonstrate  that  the  delivery  of  Ap4A  is  slower  and  the
ffect  last  longer  with  non-ionic  lenses  than  ionic  lenses
ut  in  vitro  experiments  do  not  always  reﬂect  what  hap-
ens  in  vivo, suggesting  that  apart  from  in  vitro  approaches
n  vivo  experiments  are  necessary  to  fully  evaluate  the
otential  use  of  CL  as  devices  for  drug  delivery.onﬂict of interest
he  authors  do  not  have  any  ﬁnancial  interest  on  the  mate-
ials  and  instruments  used  in  this  study.
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